-
Posted by
Two Blokes Jun 28 -
Filed in
Stock
-
4 views
Kewaunee Scientific's strong FY2025 results, record backlog, and margin expansion signal a return to growth and improved business predictability. Adjusted EPS actually rose 28% year-over-year, once non-recurring items and acquisition costs are excluded, reflecting core operational strength. A 38% increase in backlog suggests robust revenue growth for FY2026, supporting a bullish outlook and more potential stock upside.
